UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice TargetHot
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.